Saūda Arābija - angļu - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

interchemie werken “de adelaar” b.v., netherlands - vitamin a, vitamin d3, vitamin e - intravitreal implant in applicator

Saūda Arābija - angļu - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

provet veterinary product ltd, turkey - tilmicosin phosphate - intravitreal implant in applicator - 250 g/ml

Saūda Arābija - angļu - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

laboratories biove, france - minerals - intravitreal implant in applicator

Saūda Arābija - angļu - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

jordan veterinary & agriculture medicines industry company (jovet), jordan - vitamin a, vitamin d3, vitamin e - intravitreal implant in applicator

Saūda Arābija - angļu - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

ivermectin - intravitreal implant in applicator - 0.80 g/ml

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - aflibercept - solution for injection - 40mg/1ml

Izraēla - angļu - Ministry of Health

abbvie biopharmaceuticals ltd, israel - dexamethasone - implant in applicator - dexamethasone 0.7 mg - dexamethasone - dexamethasone - ozurdex is indicated for the treatment of adult patients with:• diabetic macular oedema (dme)• macular oedema following either branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo).• inflammation of the posterior segment of the eye presenting as non-infectious uveitis.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - brolucizumab, quantity: 120 mg/ml - injection, solution - excipient ingredients: water for injections; polysorbate 80; sucrose; sodium citrate - beovu is indicated for the treatment of: ? neovascular (wet) age-related macular degeneration (amd). ? diabetic macular oedema (dme).

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ranibizumab, quantity: 1.65 mg - injection, solution - excipient ingredients: histidine; histidine hydrochloride monohydrate; trehalose dihydrate; polysorbate 20; water for injections - lucentis (ranibizumab) is indicated in adults for:,- the treatment of neovascular (wet) age-related macular degeneration (amd),- the treatment of visual impairment due to diabetic macular oedema (dme),- the treatment of proliferative diabetic retinopathy (pdr),- the treatment of visual impairment due to choroidal neovascularisation.,- the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm),- the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo)

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ranibizumab, quantity: 2.3 mg - injection, solution - excipient ingredients: histidine; histidine hydrochloride monohydrate; trehalose dihydrate; polysorbate 20; water for injections - lucentis (ranibizumab) is indicated in adults for:,? the treatment of neovascular (wet) age-related macular degeneration (amd), ? the treatment of visual impairment due to diabetic macular oedema (dme), ? treatment of proliferative diabetic retinopathy (pdr), ? the treatment of visual impairment due to choroidal neovascularisation, ? the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm), ? the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo).,lucentis is indicated in preterm infants for:,? the treatment of retinopathy of prematurity (rop) with zone i (stage 1+, 2+, 3 or 3+), zone ii (stage 3+) or ap-rop (aggressive posterior rop) disease.